A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The current COVID-19 pandemic has a devastating global impact and is caused by the SARS-CoV-2 virus. SARS-CoV-2 attaches to human host cells through interaction of its receptor binding domain (RBD) located on the viral Spike (S) glycoprotein with angiotensin converting enzyme-2 (ACE2) on the surface of host cells. RBD binding to ACE2 is a critical first step in SARS-CoV-2 infection. Viral attachment occurs in dynamic environments where forces act on the binding partners and multivalent interactions play central roles, creating an urgent need for assays that can quantitate SARS-CoV-2 interactions with ACE2 under mechanical load and in defined geometries. Here, we introduce a tethered ligand assay that comprises the RBD and the ACE2 ectodomain joined by a flexible peptide linker. Using specific molecular handles, we tether the fusion proteins between a functionalized flow cell surface and magnetic beads in magnetic tweezers. We observe repeated interactions of RBD and ACE2 under constant loads and can fully quantify the force dependence and kinetics of the binding interaction. Our results suggest that the SARS-CoV-2 ACE2 interaction has higher mechanical stability, a larger free energy of binding, and a lower off-rate than that of SARS-CoV-1, the causative agents of the 2002-2004 SARS outbreak. In the absence of force, the SARS-CoV-2 RBD rapidly (within ≤1 ms) engages the ACE2 receptor if held in close proximity and remains bound to ACE2 for 400-800 s, much longer than what has been reported for other viruses engaging their cellular receptors. We anticipate that our assay will be a powerful tool investigate the roles of mutations in the RBD that might alter the infectivity of the virus and to test the modes of action of neutralizing antibodies and other agents designed to block RBD binding to ACE2 that are currently developed as potential COVID-19 therapeutics.
Article activity feed
-
SciScore for 10.1101/2020.09.27.315796: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources For preparing the IVTT expression mix, 50 µl of the HeLa lysate was mixed with 10 µl of accessory proteins. HeLasuggested: NoneSoftware and Algorithms Sentences Resources Cloning and Protein Construct Design: Constructs for ACE2-linker-RBD of SARS-CoV-1 were designed in SnapGene Version 4.2.11 SnapGenesuggested: (SnapGene, RRID:SCR_015052)All analyses were performed with custom scripts in MATLAB. MATLABsuggested: (MATLAB, RRID:SCR_001622)Res…
SciScore for 10.1101/2020.09.27.315796: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources For preparing the IVTT expression mix, 50 µl of the HeLa lysate was mixed with 10 µl of accessory proteins. HeLasuggested: NoneSoftware and Algorithms Sentences Resources Cloning and Protein Construct Design: Constructs for ACE2-linker-RBD of SARS-CoV-1 were designed in SnapGene Version 4.2.11 SnapGenesuggested: (SnapGene, RRID:SCR_015052)All analyses were performed with custom scripts in MATLAB. MATLABsuggested: (MATLAB, RRID:SCR_001622)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-